Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Accumulated Depreciation: 2015-2022

Historic Accumulated Depreciation for Spyre Therapeutics (SYRE) over the last 8 years, with Dec 2022 value amounting to $4.1 million.

  • Spyre Therapeutics' Accumulated Depreciation rose 47.89% to $4.1 million in Q4 2022 from the same period last year, while for Dec 2022 it was $4.1 million, marking a year-over-year increase of 47.89%. This contributed to the annual value of $4.1 million for FY2022, which is 47.89% up from last year.
  • According to the latest figures from FY2022, Spyre Therapeutics' Accumulated Depreciation is $4.1 million, which was up 47.89% from $2.8 million recorded in FY2021.
  • In the past 5 years, Spyre Therapeutics' Accumulated Depreciation ranged from a high of $4.1 million in FY2022 and a low of $752,000 during FY2018.
  • Moreover, its 3-year median value for Accumulated Depreciation was $2.8 million (2021), whereas its average is $3.0 million.
  • Data for Spyre Therapeutics' Accumulated Depreciation shows a peak YoY spiked of 87.96% (in 2020) over the last 5 years.
  • Over the past 5 years, Spyre Therapeutics' Accumulated Depreciation (Yearly) stood at $752,000 in 2018, then soared by 40.29% to $1.1 million in 2019, then soared by 87.96% to $2.0 million in 2020, then soared by 41.30% to $2.8 million in 2021, then spiked by 47.89% to $4.1 million in 2022.